摘要
目的:探讨利伐沙班及达比加群酯在高龄老年非瓣膜性AF患者中应用的有效性及安全性。方法:回顾性分析2016年9月至2018年3月于我院心血管内科住院治疗的高龄非瓣膜性房颤患者202例(利伐沙班组116例,达比加群酯组86例),平均随访9个月,比较两组患者基本临床资料、栓塞事件和临床相关出血事件。结果:利伐沙班组和达比加群酯组各有4例患者达到有效性终点,两组药物有效性无显著性差异(P>0.05)。其中,缺血性脑卒中是最常见的栓塞事件(4/8)。利伐沙班组共有15例患者发生出血事件,达比加群酯组共有10例患者发生出血事件,两组药物安全性亦无显著性差异(P>0.05)。胃肠道出血是最常见的出血事件(7/25)。结论:利伐沙班及达比加群酯在高龄老年非瓣膜性AF患者中应用的有效性及安全性均无明显差异。
Objective:To investigate the efficacy and safety of Rivaroxaban and Dabigatran in elderly patients with non-valvular AF.Methods:A retrospective analysis of 202 elderly patients(Rivaroxaban=116,Dabigatran=86)with non-valvular atrial fibrillation hospitalized in our department of Cardiology from September 2016 to March 2018 was performed.The average follow-up period was 9 months.Comparation of the basic clinical data,the efficacy end point and clinical relevant bleeding between the two groups were done.Results:The efficacy end point occurred in 4 patients in the Rivaroxaban group and the Dabigatran group respectively.There was no significant difference in efficacy between the two groups(P>0.05).Ischemic stroke was the most common thromboembolic events(4/8).Clinical relevant bleeding occurred in 15 patients in the Rivaroxaban group and 10 in the Dabigatran group.There was no significant difference in safety between the two groups(P>0.05).Gastrointestinal bleeding was the most common bleeding events(7/25).Conclusions:The efficacy and safety of Rivaroxaban and Dabigartran in elderly patients with non-valvular AF are similar.
作者
高逸凡
林莹
孙哲
郭新红
徐勇
GAO Yi-fan;LIN Ying;SUN Zhe;GUO Xin-hong;XU Yong(Department of Cardiology,The First Medical Center of PLA General Hospital,Beijing,100853,China)
出处
《现代生物医学进展》
CAS
2019年第13期2486-2489,共4页
Progress in Modern Biomedicine
基金
军队重大科研项目子课题(AWS14R010)
作者简介
高逸凡(1993-),硕士研究生,主要研究方向:心血管病学,E-mail:gyfran0202@163.com;通讯作者:徐勇(1965-),博士生导师,主任医师,教授,主要研究方向:心血管病学,E-mail:13701141929@163.com,电话:13701141929
